Pharmacokinetic evaluation of armodafinil for the treatment of bipolar depression

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 9, 2012, Pages 1189-1197

  Niemegeers, Peter ^a   Maudens, Kristof E ^b   Morrens, Manuel ^b,c   Patteet, Lisbeth ^b   Joos, Leen ^a   Neels, Hugo ^b,e   Sabbe, Bernard G C ^a,d  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c Psychiatric Hospital Broeders Alexianen   (Belgium)

^d Psychiatric Centre Sint Norbertushuis   (Belgium)

^e Laboratory for TDM and Toxicology   (Belgium)

Author keywords

Armodafinil; Bipolar disorder; Modafinil; Pharmacokinetics

Indexed keywords

ALPRAZOLAM; ARIPIPRAZOLE; ARMODAFINIL; BUPRENORPHINE; CARBAMAZEPINE; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; DIAZEPAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GALANTAMINE; HALOPERIDOL; MIDAZOLAM; MOCLOBEMIDE; MODAFINIL; PIMOZIDE; PLACEBO; QUETIAPINE; SERTINDOLE; ZOLPIDEM; ZOPICLONE;

AGGRESSION; AGITATION; ANXIETY; ARTICLE; BIPOLAR DEPRESSION; BLOOD PRESSURE; DELUSION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ENZYME INDUCTION; ENZYME INHIBITION; EOSINOPHILIA; FATIGUE; HALLUCINATION; HEADACHE; HEART PALPITATION; HUMAN; HYPERSENSITIVITY REACTION; INSOMNIA; IRRITABILITY; MANIA; NARCOLEPSY; NAUSEA; NERVOUSNESS; NONHUMAN; PHARMACODYNAMICS; PULSE RATE; RASH; SHIFT WORK DISORDER; SIDE EFFECT; SLEEP APNEA SYNDROME; STEVENS JOHNSON SYNDROME; SUICIDAL IDEATION; TOXIC EPIDERMAL NECROLYSIS; UPPER ABDOMINAL PAIN; XEROSTOMIA;

BENZHYDRYL COMPOUNDS; BIPOLAR DISORDER; CENTRAL NERVOUS SYSTEM STIMULANTS; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS;

EID: 84865340149     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.708338     Document Type: Article

References (60)

1. Diagnostic and statistical manual of mental health disorders. 4th edition. American Psychiatric Association; Washington DC: 1994
2. Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 2011;68(3):241-51
3. Treuer T, Tohen M. Predicting the course and outcome of bipolar disorder: a review. Eur Psychiatry 2010;25(6):328-33
4. Novick DM, Swartz HA, Frank E. Suicide attempts in bipolar I and bipolar II disorder: a review and meta-analysis of the evidence. Bipolar Disord 2010;12(1):1-9
5. Perlis RH, Ostacher MJ, Patel JK, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2006;163(2):217-24 (Pubitemid 44480840)
6. Fagiolini A, Kupfer DJ, Masalehdan A, et al. Functional impairment in the remission phase of bipolar disorder. Bipolar Disord 2005;7(3):281-5 (Pubitemid 40778891)
7. Michalak EE, Yatham LN, Lam RW. Quality of life in bipolar disorder: a review of the literature. Health Qual Life Outcomes 2005;3:72
8. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009;11(3):225-55
9. Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 2009;10(2):85-116
10. Yildiz A, Vieta E, Leucht S, Baldessarini RJ. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology 2011;36(2):375-89
11. Calabrese JR, Hirschfeld RM, Frye MA, Reed ML. Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a U.S. community-based sample. J Clin Psychiatry 2004;65(11):1499-504
12. Vieta E, Locklear J, Gunther O, et al. Treatment options for bipolar depression: a systematic review of randomized, controlled trials. J Clin Psychopharmacol 2010;30(5):579-90
13. Cruz N, Sanchez-Moreno J, Torres F, et al. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. Int J Neuropsychopharmacol 2010;13(1):5-14
14. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60(11):1079-88 (Pubitemid 37429647)
15. De Fruyt J, Deschepper E, Audenaert K, et al. Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis. J Psychopharmacol 2012;26(5):603-17
16. Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry 2010;11(2):81-109
17. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 2009; 194(1):4-9
18. Bond DJ, Lam RW, Yatham LN. Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis. J Affect Disord 2010;124(3):228-34
19. Frye MA, Grunze H, Suppes T, et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry 2007;164(8):1242-9 The only trial of modafinil in the treatment of bipolar disorder. (Pubitemid 47292414)
20. Tondo L, Vazquez G, Baldessarini RJ. Mania associated with antidepressant treatment: comprehensive meta-analytic review. Acta Psychiatr Scand 2010; 121(6):404-14
21. Ghaemi SN, Wingo AP, Filkowski MA, Baldessarini RJ. Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks. Acta Psychiatr Scand 2008;118(5):347-56
22. Sidor MM, Macqueen GM. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry 2011;72(2): 156-67
23. Malhi GS, Tanious M, Das P, Berk M. The science and practice of lithium therapy. Aust NZ J Psychiatry 2012; 46(3):192-211
24. Pramyothin P, Khaodhiar L. Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obes 2010;17(5):460-6
25. Gao K, Kemp DE, Ganocy SJ, et al. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 2008;28(2):203-9 ™ (Pubitemid 351417126)
26. NUVIGIL (armodafinil) tablets (C-IV). Cephalon, Inc. Frazer, PA: Cephalon, Inc. 2010.Available from: http://www.nuvigil.com/media/Full- PrescribingInformation.pdf [Last accessed 21 March 2012]
27. Calabrese JR, Ketter TA, Youakim JM, et al. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry 2010;71(10):1363-70 The only trial of armodafinil in the treatment of bipolar disorder.
28. ClinicalTrials.gov. U.S. National Institutes of Health. Bethesda, MD: US National Library of Medicine. 2000. Available from: http://www.clinicaltrials. gov [Last accessed 21 March 2012]
29. Dinges DF, Arora S, Darwish M, Niebler GE. Pharmacodynamic effects on alertness of single doses of armodafinil in healthy subjects during a nocturnal period of acute sleep loss. Curr Med Res Opin 2006;22(1):159-67 (Pubitemid 43106919)
30. Wisor JP, Dement WC, Aimone L, et al. Armodafinil, the R-enantiomer of modafinil: wake-promoting effects and pharmacokinetic profile in the rat. Pharmacol Biochem Behav 2006;85(3):492-9 (Pubitemid 46097059)
31. Beck P, Odle A, Wallace-Huitt T, et al. Modafinil increases arousal determined by P13 potential amplitude: an effect blocked by gap junction antagonists. Sleep 2008;31(12):1647-54
32. Urbano FJ, Leznik E, Llinas RR. Modafinil enhances thalamocortical activity by increasing neuronal electrotonic coupling. Proc Natl Acad Sci USA 2007;104(30):12554-9 (Pubitemid 47206176)
33. Code of Federal Regulations Title 21, Section 1308.14 Schedule IV. U.S. Departement of Justice, Drug Enforcement Administration. Springfield, VA: Office of Diversion Control. 2011.Available from: http://www.deadiversion.usdoj.gov/ 21cfr/cfr/1308/1308-14.htm [Last accessed 21 March 2012]
34. List of Prohibited Substances and Methods. World Anti-Doping Agency. Montreal: World Anti-Doping Agency. 2011.Available from: http://list.wada-ama. org [Last accessed 21 March 2012]
35. Darwish M, Kirby M, Hellriegel ET, et al. Pharmacokinetic profile of armodafinil in healthy subjects: pooled analysis of data from three randomized studies. Clin Drug Investig 2009;29(2):87-100
36. Darwish M, Kirby M, Hellriegel ET, Robertson P Jr. Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives: analysis of data from three randomized, single-dose, pharmacokinetic studies. Clin Drug Investig 2009;29(9):613-23
37. Darwish M, Kirby M, Hellriegel ET. Comparison of steady-state plasma concentrations of armodafinil and modafinil late in the day following morning administration: post hoc analysis of two randomized, double-blind, placebo-controlled, multiple-dose studies in healthy male subjects. Clin Drug Investig 2009;29(9):601-12
38. Robertson P Jr, Hellriegel ET. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 2003;42(2):123-37 (Pubitemid 36188553)
39. Wong YN, King SP, Simcoe D, et al. Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects. J Clin Pharmacol 1999;39(3):281-8 (Pubitemid 29148551)
40. Darwish M, Kirby M, Robertson P Jr, Hellriegel ET. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. Clin Pharmacokinet 2008;47(1):61-74 (Pubitemid 350260889)
41. Darwish M, Kirby M, Hellriegel ET, et al. Systemic exposure to armodafinil and its tolerability in healthy elderly versus young men: an open-label, multiple-dose, parallel-group study. Drugs & Aging 2011;28(2):139-50
42. Menza MA, Kaufman KR, Castellanos A. Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry 2000;61(5):378-81 (Pubitemid 30345941)
43. Camacho A, Ng B, Frye MA. Modafinil for bipolar depression with comorbid methamphetamine abuse. Am J Addict 2010;19(2):190-1
44. Even C, Thuile J, Santos J, Bourgin P. Modafinil as an adjunctive treatment to sleep deprivation in depression. J Psychiatry Neurosci 2005;30(6):432-3 (Pubitemid 41812491)
45. Fernandes PP, Petty F. Modafinil for remitted bipolar depression with hypersomnia. Ann Pharmacother 2003;37(12):1807-9 (Pubitemid 37466577)
46. Berigan T. Modafinil treatment of excessive sedation associated with divalproex sodium. Can J Psychiatry 2004;49(1):72-3 (Pubitemid 38182026)
47. Schoenknecht P, Olbrich S, Sander C, et al. Treatment of acute mania with modafinil monotherapy. Biol Psychiatry 2010;67(11):e55-7
48. Harsh JR, Hayduk R, Rosenberg R, et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin 2006;22(4):761-74
49. Roth T, White D, Schmidt-Nowara W, et al. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. Clin Ther 2006;28(5):689-706 (Pubitemid 44067263)
50. Biederman J, Swanson JM, Wigal SB, et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics 2005;116(6):e777-84 (Pubitemid 46056456)
51. Wingo AP, Ghaemi SN. Frequency of stimulant treatment and of stimulant-associated mania/hypomania in bipolar disorder patients. Psychopharmacol Bull 2008;41(4): 37-47
52. Crosby MI, Bradshaw DA, McLay RN. Severe mania complicating treatment of narcolepsy with cataplexy. J Clin Sleep Med 2011;7(2):214-16
53. Nasr S, Wendt B, Steiner K. Absence of mood switch with and tolerance to modafinil: a replication study from a large private practice. J Affect Disord 2006;95(1-3):111-14 (Pubitemid 46107016)
54. Darwish M, Bond M, Hellriegel ET, et al. Investigation of a possible interaction between quetiapine and armodafinil in patients with schizophrenia: an open-label, multiple-dose study. J Clin Pharmacol 2011;published online 8 september 2011. doi: 10.1177/0091270011414572
55. Drugs@FDA: FDA Approved Drug Products; U.S. Food and Drug Administration. Silver Spring, MD: U.S. Food and Drug Administration, 2012. Available from: http://www.accessdata. fda.gov/scripts/cder/drugsatfda/index.cfm [Last accessed 23 March 2012]
56. Kaplan KA, Gruber J, Eidelman P, et al. Hypersomnia in inter-episode bipolar disorder: does it have prognostic significance? J Affect Disord 2011;132(3):438-44
57. Candy M, Jones L, Williams R, et al. Psychostimulants for depression. Cochrane Database Syst Rev 2008(2):CD006722
58. Saavedra-Velez C, Yusim A, Anbarasan D, Lindenmayer JP. Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review. J Clin Psychiatry 2009;70(1):104-12
59. Brady KT, Gray KM, Tolliver BK. Cognitive enhancers in the treatment of substance use disorders: clinical evidence. Pharmacol Biochem Behav 2011;99(2):285-94
60. Joos L, Docx L, Schmaal L, et al. Modafinil in psychiatric disorders: the promising state reconsidered. Tijdschr Psychiatr 2010;52(11):763-73